Haoxi Health Technology Limited Class A Ordinary Shares (HAO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Haoxi Health Technology Limited Class A Ordinary Shares stock (HAO) is currently trading at $1.26. Haoxi Health Technology Limited Class A Ordinary Shares PE ratio is 0.88. Haoxi Health Technology Limited Class A Ordinary Shares PS ratio (Price-to-Sales) is 2.11. WallStSmart rates HAO as Sell.
- HAO PE ratio analysis and historical PE chart
- HAO PS ratio (Price-to-Sales) history and trend
- HAO intrinsic value — DCF, Graham Number, EPV models
- HAO stock price prediction 2025 2026 2027 2028 2029 2030
- HAO fair value vs current price
- HAO insider transactions and insider buying
- Is HAO undervalued or overvalued?
- Haoxi Health Technology Limited Class A Ordinary Shares financial analysis — revenue, earnings, cash flow
- HAO Piotroski F-Score and Altman Z-Score
- HAO analyst price target and Smart Rating
Haoxi Health Technology Limited Class A
📊 No data available
Try selecting a different time range
HAO Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Haoxi Health Technology Limited Class A Ordinary Shares (HAO)
HAO trades at a significant discount to its Graham intrinsic value of $61.78, offering a 98% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Haoxi Health Technology Limited Class A Ordinary Shares (HAO) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in return on equity, eps growth. Concerns around market cap and operating margin. Mixed signals suggest waiting for clearer direction before acting.
Haoxi Health Technology Limited Class A Ordinary Shares (HAO) Key Strengths (2)
Every $100 of shareholder equity generates $27 in profit
Earnings per share surging 172.70% year-over-year
Supporting Valuation Data
Haoxi Health Technology Limited Class A Ordinary Shares (HAO) Areas to Watch (7)
Losing money on operations
Revenue declining -64.60%, a shrinking business
Very low institutional interest at 0.07%
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 4.0x book value
Revenue is fairly priced at 2.11x sales
Decent profitability, keeps $12 per $100 revenue
Haoxi Health Technology Limited Class A Ordinary Shares (HAO) Detailed Analysis Report
Overall Assessment
This company scores 42/100 in our Smart Analysis, earning a D grade. Out of 9 metrics analyzed, 2 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 3.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Return on Equity, EPS Growth. Profitability is solid with Return on Equity at 27.10%. Growth metrics are encouraging with EPS Growth at 172.70%.
The Bear Case
The primary concerns are Operating Margin, Revenue Growth, Institutional Own.. Some valuation metrics including Price/Sales (2.11), Price/Book (3.98) suggest expensive pricing. Growth concerns include Revenue Growth at -64.60%, which may limit upside. Profitability pressure is visible in Operating Margin at -21.20%, Profit Margin at 11.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 27.10% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at -64.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
HAO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
HAO's Price-to-Sales ratio of 2.11x trades 23% below its historical average of 2.75x (53th percentile). The current valuation is 77% below its historical high of 9.32x set in Feb 2024, and 1307% above its historical low of 0.15x in Dec 2024. Over the past 12 months, the PS ratio has expanded from ~1.8x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Haoxi Health Technology Limited Class A Ordinary Shares (HAO) · COMMUNICATION SERVICES › ADVERTISING AGENCIES
The Big Picture
Haoxi Health Technology Limited Class A Ordinary Shares faces headwinds with declining revenue, though profitability provides a cushion. Revenue reached 33M with 65% decline year-over-year. Profit margins of 11.8% are healthy, with room for further expansion as the business scales.
Key Findings
ROE of 2710.0% means the company generates strong returns on shareholder equity. Above 20% is considered top-tier.
Revenue contracted 65% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Margin expansion: can Haoxi Health Technology Limited Class A Ordinary Shares push profit margins above 15% as the business scales?
Sector dynamics: monitor ADVERTISING AGENCIES industry trends, competitive moves, and regulatory changes that could impact Haoxi Health Technology Limited Class A Ordinary Shares.
Bottom Line
Haoxi Health Technology Limited Class A Ordinary Shares faces challenges with declining revenue. While profitability provides a buffer, the long-term trajectory needs to improve. Watch for management's strategic response and whether the company can stabilize or pivot to new growth drivers.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Haoxi Health Technology Limited Class A Ordinary Shares(HAO)
NASDAQ
COMMUNICATION SERVICES
ADVERTISING AGENCIES
USA
Haoxi Health Technology Limited Class A Ordinary Shares is a pioneering force in the health technology sector, committed to revolutionizing healthcare delivery through innovative solutions. Utilizing advanced technologies like artificial intelligence and data analytics, the company aims to enhance diagnosis, treatment efficiency, and patient management, setting new standards in healthcare practices. With a robust focus on research and development, Haoxi is well-positioned to capitalize on emerging trends in the healthcare technology landscape, presenting a significant growth opportunity for institutional investors.